Further mechanistic in vivo and in vitro studies revealed that AMPK-mediated NR4A1 repression and subsequent mitochondrial improvement might be the underlying mechanism of the therapeutic effect of SG surgery on DCM. This evidence concerns the gene NR4A1 and familial dilated cardiomyopathy.